Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

New way to improve vaccines against cancer and infectious diseases

Research groups from Charité Universitätsmedizin Berlin and the University of Geneva have discovered a new way of improving vaccines against infectious diseases and for use in cancer therapies. Scientists have shown a basic new mechanism that stimulates the body's own alarm signals in case of viral infection to animate the immune system to maximum performance.

17 Feb 2012

Scientists track initial steps of type 1 diabetes mellitus

Scientists have taken a remarkably detailed look at the initial steps that occur in the body when type 1 diabetes mellitus first develops in a child or young adult.

17 Feb 2012

Thrombocytosis linked to severity of ovarian cancer

Highly elevated platelet levels fuel tumor growth and reduce the survival of ovarian cancer patients, an international team of researchers led by scientists at The University of Texas MD Anderson Cancer center reports in the New England Journal of Medicine.

16 Feb 2012

New information about IL-6 protein's role in development of neurological disorders

A UT Dallas study is revealing new information about a key protein's role in the development of epilepsy, autism and other neurological disorders. This work could one day lead to new treatments for the conditions.

15 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012

OncoSec to commence OMS ElectroImmunotherapy Phase II trial in MCC

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.

13 Feb 2012

Benefits of long-term Kineret therapy in people with NOMID

A new study shows that Kineret (anakinra), a medication approved for the treatment of rheumatoid arthritis, is effective in stopping the progression of organ damage in people with neonatal-onset multisystem inflammatory disease.

13 Feb 2012

Scientists discover ferocity of immune system after viral infection

A scientific team led by researchers at the University of Geneva (UNIGE) and the Charité Berlin Medical University has made a completely unprecedented discovery showing how much our immune system is provoked into action when confronted by viral intruders.

10 Feb 2012

Scientists establish HCV infection in liver-like cells derived from iPSCs

Hepatitis C, an infectious disease that can cause inflammation and organ failure, has different effects on different people. But no one is sure why some people are very susceptible to the infection, while others are resistant. Scientists believe that if they could study liver cells from different people in the lab, they could determine how genetic differences produce these varying responses. However, liver cells are difficult to obtain and notoriously difficult to grow in a lab dish because they tend to lose their normal structure and function when removed from the body.

2 Feb 2012

Scientists connect two signature characteristics of pancreatic cancer

Scientists have connected two signature characteristics of pancreatic cancer, identifying a self-perpetuating "vicious cycle" of molecular activity and a new potential target for drugs to treat one of the most lehal forms of cancer.

27 Jan 2012

RBC storage duration not associated with transfusion-related pulmonary complications

There is no difference in early measures of pulmonary function, immunologic status or coagulation status after fresh versus standard issue single-unit red blood cell (RBC) transfusion, according to a new study from the Mayo Clinic.

21 Jan 2012

Researchers identify critical cellular, molecular events that lead to esophageal adenocarcinoma

Researchers at Columbia University Medical Center (CUMC) have identified the critical early cellular and molecular events that give rise to a type of esophageal cancer called esophageal adenocarcinoma, the fastest-rising solid tumor in the United States.

18 Jan 2012

Intestinal worm infections may not be bad

Intestinal worm infections may not be all bad, according to a new study by William C. Gause, PhD, and colleagues at UMDNJ- New Jersey Medical School. The researchers have found cytokines that help oust intestinal worm infections in mice also soothe associated lung injury and inflammation.

11 Jan 2012

Study examines impact of maternal obesity on inflammatory responses

A number of different immunological mechanisms ensure the successful establishment and maintenance of pregnancy. Imbalance in these mechanisms is associated with adverse pregnancy outcomes.

11 Jan 2012

Rilonacept appears safe and well-tolerated in patients with gout

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.

5 Jan 2012

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

27 Dec 2011

CEL-SCI reports net loss of $26.8M for fiscal year ended September 30, 2011

CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2011.

26 Dec 2011

Potential new strategy against bacteria with multi-drug resistant organisms

Vaccines with broader reach might be made by stimulating specialized immune cells to recognize foreign cell membrane proteins that are shared across bacterial species, say researchers from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine in a report published online today in Immunity.

23 Dec 2011

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.

14 Dec 2011

Research describes advantages of new vaccine adjuvant

New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest it could be useful for enhancing protection against a number of different infections.

13 Dec 2011